Medigene's Veregen® launched in Spain


Martinsried/Munich, June 5th, 2012. Medigene AG (MDG, Frankfurt, Prime Standard) (MDG, Frankfurt, Prime Standard) announced today that its partner BIAL Industrial Farmacéutica, S.A. has started the launch of Veregen®, for the treatment of genital warts, in Spain. Following Germany and Austria, Spain is the third European market where Veregen® is available. In addition, Veregen® is also being marketed in the United States. Medigene supplies BIAL with the drug product, and will receive royalties on sales achieved with Veregen®.

Dr. Frank Mathias, Chief Executive Officer of Medigene AG, commented: "The market launch in Spain, one of the five major European markets, represents a significant step forward in the commercialization of Veregen®. Through the marketing activities of our partner BIAL, we are pleased to offer this innovative drug to patients in Spain."

Market approvals for Veregen® have been obtained in Switzerland, Poland, Sweden, Norway, and Serbia. In March 2012, marketing authorization applications for numerous additional European countries were assessed positively by the regulatory authorities. Medigene expects that the national marketing authorizations will be formally granted by the respective regulatory authorities within the next few months.

Medigene has entered into several marketing partnerships for Veregen®, including Fougera for the United States; Abbott for Germany, Austria, and Switzerland; Laboratoires Expanscience for France; and a number of other partners across Europe, America, and Asia. Medigene is planning to continue this global licensing strategy.

Veregen®: Veregen® (previously Polyphenon E® ointment), a topical treatment for external genital warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. Medigene acquired the basic rights to the active ingredient in Veregen® from Epitome Pharmaceuticals, Inc. in 1999, and was solely responsible for the drug's successful preclinical and clinical development, as well as the approval process. Sinecatechins 15% ointment (Veregen®) is recommended as a possible option for treating genital warts by the US Department of Health and Human Services Center for Disease Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines 2010.

About BIAL: BIAL, founded in 1924, is a global pharmaceutical company with products marketed in 50 countries on 4 continents. The privately owned company ranks number 5 on the Portuguese pharmaceutical market and has a strong presence on the Iberian Peninsula, in Latin America as well as in French and Portuguese speaking countries in Africa. BIAL is strongly committed to therapeutic innovation investing more than 25% of its turnover in research and development every year. BIAL currently has several innovative programs under development, which the company expects to bring to the market within the next years, thereby strengthening its position throughout Europe. For further details, please visit


This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.


- End -

Medigene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials and is developing an innovative vaccine technology. For more information, please visit

Julia Hofmann & Kerstin Langlotz
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20

To unsubscribe from the press release distribution list, please go to